Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $1.0 million.

  • Crinetics Pharmaceuticals' Depreciation & Amortization (CF) rose 3142.86% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 6308.1%. This contributed to the annual value of $2.8 million for FY2024, which is 15364.3% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Depreciation & Amortization (CF) of $1.0 million as of Q3 2025, which was up 3142.86% from $959000.0 recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $1.0 million in Q3 2025 and a low of $215000.0 during Q2 2022
  • In the last 5 years, Crinetics Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $280000.0 in 2022 and averaged $457052.6.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first plummeted by 652.17% in 2022, then surged by 20076.34% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $235000.0 in 2021, then rose by 19.15% to $280000.0 in 2022, then fell by 6.43% to $262000.0 in 2023, then soared by 200.76% to $788000.0 in 2024, then rose by 28.43% to $1.0 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.0 million for Q3 2025, versus $959000.0 for Q2 2025 and $925000.0 for Q1 2025.